Ignite Creation Date:
2024-05-06 @ 3:05 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04514302
Status:
COMPLETED
Last Update Posted:
2023-01-26
First Post:
2020-08-12
Brief Title:
Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fab2 Fragments INOSARS for Adult Patients With Mild COVID-19
Sponsor:
Hospital San Jose Tec de Monterrey
Organization:
Hospital San Jose Tec de Monterrey
Study Overview
Official Title:
Phase I Randomized Placebo-controlled Double-blind Study to Evaluate the Safety and Antiviral Efficacy of Three Different Single Doses of Anti-SARS-CoV-2 Equine Antibody Fab2 Fragments INOSARS in Adult Patients With Mild COVID-19
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized placebo-controlled double-blind phase I clinical study of anti-SARS-CoV-2 equine immunoglobulin Fab2 fragments INOSARS to evaluate the safety and antiviral efficacy for the treatment of adult patients with mild COVID-19 and low risk of disease progression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None